Increases in neutral, Mg2+-dependent and acidic, Mg2+-independent sphingomyelinase activities precede commitment to apoptosis and are not a consequence of caspase 3-like activity in Molt-4 cells in response to thymidylate synthase inhibition by GW1843

Blood

Volumn 91, Issue 11, 1998, Pages 4350-4360

  Laethem, Ronald M ^a   Hannun, Yusuf A ^b   Jayadev, Supriya ^b   Sexton, Connie J ^b   Strum, Jay C ^b   Sundseth, Rebecca ^b   Smith, Gary K ^b  

^a GLAXOSMITHKLINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; GW 1843; SPHINGOMYELIN PHOSPHODIESTERASE; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; CASP3 PROTEIN, HUMAN; CASPASE; CASPASE 3; CERAMIDE; CYSTEINE PROTEINASE; DIACYLGLYCEROL; ENZYME INHIBITOR; ENZYME PRECURSOR; INDOLE DERIVATIVE; MAGNESIUM; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CELL DEATH; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; CELL CULTURE; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; T CELL LEUKEMIA;

APOPTOSIS; CASPASE 3; CASPASES; CERAMIDES; CYSTEINE ENDOPEPTIDASES; DIGLYCERIDES; ENZYME INHIBITORS; ENZYME PRECURSORS; HUMANS; INDOLES; LEUKEMIA, T-CELL; MAGNESIUM; QUINAZOLINES; SPHINGOMYELIN PHOSPHODIESTERASE; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0032081313     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.11.4350.411k27_4350_4360     Document Type: Article

References (54)

1. Houghton PJ, Germain GS, Hazelton BJ, Pennington JW, Houghton JA: Mutants of human colon adenocarcinoma, selected for thymi-dylate synthase deficiency. Proc Natl Acad Sci USA 86:377, 1989
2. Smith GK, Duch DS, Dev IK, Kaufmann SH: Metabolic effects and kill of T-cell leukemia by 5-deazaacyclotetrahydrofolate, a specific inhibitor of glycineamide ribonucleotide transformylase. Cancer Res 52:4895, 1992
3. Smith SG, Lehman NL, Moran RG: Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonie carcinoma cells. Cancer Res 53:5697, 1993
4. Banks SD, Waters KA, Barrett LL, Dickerson S, Pendergast W, Smith GK: Destruction of WiDr multicellular tumor spheroids with the novel thymidylate synthase inhibitor 1843U89 at physiological thymidine concentrations. Cancer Chemother Pharmacol 33:455, 1994
5. O'Connor BM, Webber S, Jackson RC, Galivan J, Rhee MS: Biological activity of a novel rationally designed lipophilic thymidylate synthase inhibitor. Cancer Chemother Pharmacol 34:225, 1994
6. Jackman AL, Boyle FT, Harrap KR: Tomudex (ZD1694): From concept to care, a programme in rational drug discovery. Invest New Drugs 14:305, 1996
7. Shili C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM: LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes, Cancer Res 57:1116, 1997
8. Smith GK, Amyx H, Boytos CM, Duch DS, Ferone R, Wilson HR: Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid. Cancer Res 55:6117, 1995
9. Duch DS, Banks S, Dev IK, Dickerson SH, Ferone R, Heath LS, Humphreys J, Knick V, Pendergast W, Singer S, Smith GK, Waters K, Wilson HR: Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res 53:810, 1993
10. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11:121, 1992
11. Hannun YA, Obeid LM: Ceramide: An intracellular signal for apoptosis. Trends Biochem Sci 20:73, 1995
12. Dbaibo GS, Pushkareva MY, Jayadev S, Schwartz JK, Horowitz JM, Obeid LM, Hannun YA: Retinoblastoma gene product as a downstream target for a ceramide-dependent pathway of growth arrest. Proc Natl Acad Sci USA 92:1347, 1995
13. Brugg B, Michel PP, Agid Y, Ruberg M: Ceramide induces apoptosis in cultured mesencephalic neurons. J Neurochem 66:733, 1996
14. Obeid LM, Linardic CM, Karolak LA, Hannun YA: Programmed cell death induced by ceramide. Science 259:1769, 1993
15. Mathias S, Dressler KA, Kolesnick RN: Characterization of a ceramide-activated protein kinase: Stimulation by tumor necrosis factor α. Proc Natl Acad Sci USA 88:10009, 1991
16. Dobrowsky RT, Hannun YA: Ceramide stimulates a cytosolic protein phosphatase. J Biol Chem 267:5048, 1992
17. Rao B, Spence M: Sphingomyelinase activity at pH 7.4 in human brain and a comparison to activity at pH 5.0. J Lipid Res 17:506, 1976
18. Barnholz Y, Roitman A, Gatt S: Enzymatic hydrolysis of sphingolipids. II. Hydrolysis of sphingomyelin by an enzyme from rat brain. J Biol Chem 241:3731, 1966
19. 2+-stimulated sphingomyelinase in fetal bovine serum. J Biol Chem 264:5358, 1989
20. 3-induced HL-60 cell differentiation. J Biol Chem 269:4070, 1994
21. Wiegmann K, Schütze S, Machleidt T, Witte D, Krönke M: Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 78:1005, 1994
22. Ballou LR, Chao CP, Holness MA, Barker SC, Raghow R: Interleukin-1-mediated PGE2 production and sphingomyelin metabolism. Evidence for the regulation of cyclooxygenase gene expression by sphingosine and ceramide. J Biol Chem 267:20044, 1992
23. Mathias S, Younes A, Kan C-C, Orlow I, Joseph C, Kolesnick RN: Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-Iβ. Science 259:519, 1993
24. Kuno K, Matsushima K: The IL-1 receptor signaling pathway. J Leukoc Biol 56:542, 1994
25. Gulbins E, Bissonnette R, Mahboubi A, Martin S, Nishioka W, Brunner T, Baier G, Baier-Bitterlich G, Byrd C, Lang F, Kolesnick R, Altman A, Green D: FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunity 2:341, 1995
26. Pendergast W, Dickerson SH, Dev IK, Ferone R, Duch DS, Smith GK: Benzo[f]quinazoline inhibitors of thymidylate synthase: Methyle-neamino-linked arylglutamate derivatives. J Med Chem 37:838, 1994
27. Kaufmann SH: Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: A cautionary note. Cancer Res 49:5870, 1989
28. Preston GA, Lang JE, Maronpot RR, Barren JC: Regulation of apoptosis by low serum in cells of different stages of neoplastic progression: Enhanced susceptibility after loss of a senescence gene and decreased susceptibility after loss of a tumor suppressor gene. Cancer Res 54:4214, 1994
29. Smith GK, Duch DS, Dev IK, Kaufmann SH: Metabolic effects and kill of human T-cell leukemia by 5-deazaacyclotetrahydrofolate, a specific inhibitor of glycineamide ribonucleotide transformylase. Cancer Res 52: 4895, 1992
30. Bligh EG, Dyer WJ: A rapid method of lipid extraction and purification. Can J Biochem Physiol 37:911, 1959
31. Ames BN, Dubin DT: The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid. J Biol Chem 235:769, 1960
32. Jayadev S, Linardic CM, Hannun YA: Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor α. J Biol Chem 269:5757, 1994
33. Bortner CD, Oldenburg NBE, Cidlowski JA: The role of DNA fragmentation in apoptosis. Trends Cell Biol 5:21, 1995
34. de Murcia G, Ménissier de MurciaJ: Poly(ADP-ribose) polymerase: A molecular nick-sensor. Trends Biochem Sci 19:172, 1994
35. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bc1-2 and Abl. J Exp Med 182:1545, 1995
36. Martin SJ, Finucane DM, Amarante-Mendes GP, O'Brien GA, Green DR: Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity. J Biol Chem 271:28753, 1996
37. Cifone MG, De Maria R, Roncaioli P, Rippo MR, Azuma M, Lanier LL, Santoni A, Testi R: Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J Exp Med 177:1547, 1993
38. Adain-Klages S, Adam D, Wiegmann K, Struve S, Kolanus W, Schneider-Mergener J, Krönke M: FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase. Cell 86:937, 1996
39. Lilly M, Brown C, Pettit G, Kraft A: Bryostatin 1: A potential anti-leukemic agent for chronic myelomonocytic leukemia. Leukemia 5:283, 1991
40. Xue D, Shaham S, Horvitz HR: The Caenorhabditis elegans cell-death protein CED-3 is a cysteine protease with substrate specificities similar to those of the human CPP32 protease. Genes Dev 10:1073, 1996
41. Margolin N, Raybuck SA, Wilson KP, Chen W, Fox T, Gu Y, Livingston DJ: Substrate and inhibitor specificity of interleukin-1 beta-converting enzyme and related caspases. J Biol Chem 272:7223, 1997
42. Dubrez L, Savoy I, Hamman A, Solary E: Pivotal role of a DEVD-sensitive step in etoposide-induced and Fas-mediated apoptotic pathways. EMBO J 15:5504, 1996
43. Jarvis WD, Fornari FA, Browning JL, Gewirtz DA, Kolesnick RN. Grant S: Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells. J Biol Chem 269:31685, 1994
44. Jarvis WD, Kolesnick RN, Fornari FA, Traylor RS, Gewirtz DA, Grant S: Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proc Natl Acad Sci USA 91:73, 1994
45. Tepper CG, Jayadev S, Liu B, Bielawska A, Wolff R, Yonehara S, Hannun YA, Seldin MF: Role for ceramide as an endogenous mediator of Fas-induced cytotoxicity. Proc Natl Acad Sci USA 92:8443, 1995
46. Smyth MJ, Perry DK, Zhang J, Poirier GG, Hannun YA, Obeid LM: prICE: A downstream target for ceramide-induced apoptosis and for the inhibitory action of Bc1-2. Biochem J 316:25, 1996
47. Dbaibo GS, Perry DK, Gamard CJ, Platt R, Poirier GG, Obeid LM, Hannun YA: Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)-alpha: CrmA and Bc1-2 target distinct components in the apoptotic pathway. J Exp Med 185:481, 1997
48. Xiang J, Chao DT, Korsmeyer SJ: BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. Proc Natl Acad Sci USA 93:14559, 1996
49. Santana P, Pena LA, Haimovitz-Friedman A, Martin S, Green D, McLoughlin M, Cordon-Cardo C, Schuehman EH, Fuks Z, Kolesnick R: Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 86:189, 1996
50. Wiesner DA, Kilkus JP, Gottschalk AR. Quintans J, Dawson G: Anti-immunoglobulin-induced apoptosis in WEHI 231 cells involves the slow formation of ceramide from sphingomyelin and is blocked by bcl-XL. J Biol Chem 272:9868. 1997
51. Chmura SJ, Nodzenski E, Beckett MA, Kufe DW, Quintans J, Weichselbaum RR: Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res 57:1270, 1997
52. Adam D, Wiegmann K, Adam-Klages S, Ruff A, Krönke M: A novel cytoplasmic domain of the p55 TNF receptor initiates the neutral sphingomyelinase pathway. J Biol Chem 271:14617, 1996
53. Su X, Zhou T, Wang Z, Yang P, Jope RS, Mountz JD: Defective expression of hematopoietic cell protein tyrosine phosphatase (HCP) in lymphoid cells blocks Fas-mediated apoptosis. Immunity 2:353, 1995
54. Sundseth R, Singer S, Yates B, Smith G, Ferone R, Dev I: Thymineless apoptotic death induced by 1843U89 in human tumor cell lines is independent of dUTP accumulation and misincorporation of dUMP into DNA. Proc Amer Assoc Cancer Res 38:476, 1997 (abstr)